Osimertinib given as first-line treatment may alter biology of EGFR mutated NSCLC
The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking ...
Apr 14, 2016
0
0